New therapy to treat advanced small cell lung cancer approved for Australian patients

Specialised Therapeutics

14 September 2021 - Zepzelca approval granted under a provisional regulatory pathway.

Australian patients with an aggressive form of lung cancer (metastatic small cell lung cancer) can now access a new therapy that may improve outcomes.

The therapy, Zepzelca (lurbinectedin) has been approved by the Therapeutic Goods Administration "for the treatment of patients with metastatic small cell lung cancer that has progressed on or after prior platinum-containing therapy".

Read Specialised Therapeutics press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , Australia